The possibility of Opto-therapeutics to treat AD and other related tauopathies was demonstrated in a new study (Binder et al., 2020) that showed optical stimulation upon blue-light (465 nm) illumination can lead to TFEB expression, translocation into the nucleus, and activation, which can further induce autophagy and lysosomal gene expression and ultimately clear pathological Tau from neuronal cells and iPSC-differentiated neurons from an AD patient. The gene discussed is TFEB; the disease is tauopathy.